Please assess the completion status of the following clinical trial:

Trial Title: Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. hepatic cirrhosis patients after 7days treatment of loop diuretics and aldosterone antagonist but still with ascites~2. Hospitalized patients or those who can be hospitalized in this trial between observation period and posttherapeutic observation (Visits at clinic will be allowed after day 8);~3. During the observation period (-3 day to -1 day ), subjects whose body weight difference fall within ±1.0 kg range 2 days (day-2 and day -1) prior to initiation of trial drug treatment;~4. Ages: ≥18 and ≤75 years of age;~5. Genders: men or women;~6. Signed the Informed Consent Form.~Exclusion Criteria:~1. Patients with the following diseases, complications or symptoms:~   * Hepatic encephalopathy (Coma scale Note 1) grade 2 or higher);~  * Malignant ascites;~  * Uncontrolled spontaneous bacterial peritonitis;~  * Patients are likely to experience alimentary tract hemorrhage during the trial;~  * Heart failure (NYHA cardiac function scale Note 2) stages 3 and 4);~  * Anuria (daily urine volume below 100mL);~  * Dysuria resulting from urethral stricture, calculus and tumors.~2. Patients with the following medical history:~   * Alimentary tract hemorrhage within 10 days prior to screening;~  * Cerebrovascular accident within 1 month prior to screening;~  * Gout attack within 1 month prior to screening;~  * Past allergy or hypersensitive reactions to benzodiazepines (e.g. benazepril hydrochloride)~3. Systolic pressure below 90mmHg at screening;~4. Patients with the following abnormalities in laboratory examinations at screening:~   Serum creatinine exceeds 2.5X upper limits of normal, serum Na+\>145mmol/L (or exceeds upper limits of normal), serum K+\>5.5mmol/L, uric acid\>8.0mg/dL (476μmol/L), Child-pugh scale greater than 12.~5. Patients cannot take drugs orally;~6. Pregnant or breast-feeding patients or women at child-bearing ages without taking acceptable contraceptive measures;~7. Patients received albumin or other blood preparations within 4 days prior to trial drug administration;~8. Patients participated in clinical trials of other drugs within 1 month prior to screening;~9. Patients participated in tolvaptan trials and took tolvaptan previously;~10. Patients are unsuitable to participate in this trial in investigators' opinion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1. tolvaptan (Type: EXPERIMENTAL): 15 mg, P.O., Qd, for 7 days,
- 2 tolvaptan (Type: EXPERIMENTAL): 30 mg, P.O., Qd, for 7 days,
- 3. Placebo (Type: EXPERIMENTAL): 30mg,P.O.,Qd, for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).